Form 4 Filing for Avalo Therapeutics, Inc.

This filing details transactions by Samantha Truex, a director at Avalo Therapeutics, Inc. On March 28, 2026, Truex acquired 3,166 shares of Common Stock and simultaneously disposed of 3,166 Restricted Stock Units. These Restricted Stock Units converted into Common Stock on a one-for-one basis. The acquisition of Common Stock was a non-derivative transaction, while the disposal of RSUs was a derivative transaction. Following these transactions, Truex holds 6,333 shares of Common Stock. The RSUs were granted on August 13, 2024, with vesting schedules extending to March 28, 2027, contingent upon continued service. The reported transactions are part of her compensation and equity incentive plan.